Details for Patent: 8,110,553
✉ Email this page to a colleague
Which drugs does patent 8,110,553 protect, and when does it expire?
Patent 8,110,553 protects LINZESS and is included in one NDA.
This patent has eighty-seven patent family members in twenty-eight countries.
Summary for Patent: 8,110,553
| Title: | Methods and compositions for the treatment of gastrointestinal disorders |
| Abstract: | The present invention features compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), Crohn's disease, ulcerative colitis, Inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation (post-operative ileus), and constipation associated with neuropathic disorders as well as other conditions and disorders using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor. |
| Inventor(s): | Currie; Mark G. (Sterling, MA), Mahajan-Miklos; Shalina (Stanford, CA), Milne; G. Todd (Brookline, MA), Norman; Thea (Cambridge, MA) |
| Assignee: | Ironwood Pharmaceuticals, Inc. (Cambridge, MA) |
| Application Number: | 12/788,979 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,110,553 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 8,110,553
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie | LINZESS | linaclotide | CAPSULE;ORAL | 202811-003 | Jan 25, 2017 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | TREATMENT OF FUNCTIONAL CONSTIPATION IN PEDIATRIC PATIENTS 6 TO 17 YEARS OF AGE | ⤷ Try a Trial | ||||
| Abbvie | LINZESS | linaclotide | CAPSULE;ORAL | 202811-003 | Jan 25, 2017 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | METHOD OF TREATING CHRONIC IDIOPATHIC CONSTIPATION IN ADULT PATIENTS. | ⤷ Try a Trial | ||||
| Abbvie | LINZESS | linaclotide | CAPSULE;ORAL | 202811-001 | Aug 30, 2012 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | METHOD OF TREATING IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN ADULTS | ⤷ Try a Trial | ||||
| Abbvie | LINZESS | linaclotide | CAPSULE;ORAL | 202811-002 | Aug 30, 2012 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | METHOD OF TREATING IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN ADULTS | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,110,553
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | E365174 | ⤷ Try a Trial | |||
| Austria | E477268 | ⤷ Try a Trial | |||
| Australia | 2004210161 | ⤷ Try a Trial | |||
| Australia | 2005222387 | ⤷ Try a Trial | |||
| Australia | 2009235993 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
